“Tonight we hosted a dinner with VYGR just after the announcement that SNY did not.”,” the firm’s analyst commented.
Other equities research analysts also recently issued research reports about the stock. Canaccord Genuity began coverage on shares of Voyager Therapeutics in a research note on Friday, October 27th. They set a buy rating and a $35.00 price target on the stock. Stifel Nicolaus restated a buy rating and issued a $31.00 target price (up previously from $20.00) on shares of Voyager Therapeutics in a research note on Monday, October 23rd. ValuEngine upgraded shares of Voyager Therapeutics from a sell rating to a hold rating in a research note on Saturday, September 30th. Chardan Capital restated a hold rating on shares of Voyager Therapeutics in a research note on Sunday, September 10th. Finally, Evercore ISI began coverage on shares of Voyager Therapeutics in a research note on Wednesday, August 16th. They issued an outperform rating and a $12.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $28.89.
Shares of Voyager Therapeutics (NASDAQ VYGR) opened at $16.89 on Tuesday.
Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.62) by ($0.11). Voyager Therapeutics had a negative return on equity of 60.63% and a negative net margin of 1,195.63%. The business had revenue of $1.18 million for the quarter, compared to analyst estimates of $3.27 million. equities research analysts predict that Voyager Therapeutics will post -2.86 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/11/04/voyager-therapeutics-vygr-buy-rating-reiterated-at-cowen-and-company.html.
In other Voyager Therapeutics news, insider Bernard Ravina sold 5,490 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $10.00, for a total transaction of $54,900.00. Following the completion of the sale, the insider now directly owns 17,157 shares of the company’s stock, valued at approximately $171,570. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 32,940 shares of company stock valued at $490,092 over the last three months. Company insiders own 8.00% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its stake in shares of Voyager Therapeutics by 20.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock valued at $477,000 after acquiring an additional 9,207 shares during the last quarter. Hershey Trust Co. increased its stake in shares of Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after acquiring an additional 8,921 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Voyager Therapeutics by 17.4% in the 1st quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock valued at $1,739,000 after acquiring an additional 19,450 shares during the last quarter. Bessemer Group Inc. increased its stake in shares of Voyager Therapeutics by 148.1% in the 2nd quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock valued at $402,000 after acquiring an additional 26,763 shares during the last quarter. Finally, HarbourVest Partners LLC bought a new stake in shares of Voyager Therapeutics in the 2nd quarter valued at about $400,000. 40.72% of the stock is owned by hedge funds and other institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
What are top analysts saying about Voyager Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Voyager Therapeutics Inc. and related companies.